Rheostat Therapeutics Announces $23 Million Series A Financing; To Develop Potential Treatments for Neurodegenerative Diseases
26 nov. 2018 09h00 HE
|
Rheostat Therapeutics
CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today...
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
01 nov. 2018 02h00 HE
|
Denali Therapeutics Inc.
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseasesDenali to receive...
Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer
07 août 2018 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Reports First Quarter 2018 Financial Results
11 mai 2018 08h00 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
08 févr. 2018 09h00 HE
|
Denali Therapeutics Inc.; Lonza Pharma & Biotech
Partnership aims to develop drugs for neurodegenerative diseasesDenali will draw on Lonza’s expertise in developing and manufacturing complex biologic molecules BASEL, Switzerland and SOUTH SAN...
Denali Therapeutics Announces Pricing of Initial Public Offering
07 déc. 2017 19h08 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of 13,888,888 shares of its common...
DiamiR Announces Oral Presentation at AD/PD(TM) 2017
29 mars 2017 08h02 HE
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 29, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Samuil...
DiamiR to Present at the GTCbio Biomarker Summit 2017
20 mars 2017 08h02 HE
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 20, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira...
DiamiR Announces Oral Presentation at Biomarkers Summit 2016
18 mars 2016 08h02 HE
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 18, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that...
Jackson Laboratory researchers discover mutation involved in neurodegeneration
06 oct. 2015 08h52 HE
|
The Jackson Laboratory
BAR HARBOR, Maine, Oct. 6, 2015 (GLOBE NEWSWIRE) -- A mutation that increases the level of a special class of sphingolipids—molecules important to cell structure and signaling—can lead to...